Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Hepatitis C, Chronic 2Virus Diseases 1Liver Diseases 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 2Ribavirin 2sofosbuvir-velpatasvir drug combination 1pembrolizumab 1navitoclax 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1hepatitis C immune globulin, human 1grazoprevir 1elbasvir-grazoprevir drug combination 1elbasvir 1Sofosbuvir 1Rapid Diagnostic Tests 1Raltegravir Potassium 1Patient Navigation 1Introns 1Immunoglobulin G 1Immunoenzyme Techniques 1Enzyme-Linked Immunosorbent Assay 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hepatitis C × ledipasvir, sofosbuvir drug combination × Clear all
NCT02868242 2020-03-02

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Gilead Sciences

Phase 2 Completed
19 enrolled 14 charts

Hepatitis C, Liver Diseases, Virus Diseases, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡